November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

New Diagnostic Method Aims to Pinpoint Problematic Gut Bacteria in Inflammatory Bowel Disease

🧠 AI Analysis 2 min read 👁 5

Researchers have developed a technique to identify specific bacteria that drive chronic gut inflammation, opening the door to targeted treatments for Crohn's disease and ulcerative colitis.

New Diagnostic Method Aims to Pinpoint Problematic Gut Bacteria in Inflammatory Bowel Disease🧠AI Analysis

Photo: Medical Xpress

Key points

  • Researchers identified two bacterial species, Sarcina perfringens and Hathewaya massiliensis, linked to intestinal inflammation.
  • A screening of 1,518 compounds found five substances that selectively inhibit these bacteria without harming the broader microbiome.
  • The method requires further clinical trials in humans to confirm its safety and therapeutic efficacy.

An international team of scientists has unveiled a novel approach designed to detect and selectively inhibit gut bacteria responsible for triggering or worsening chronic intestinal inflammation. Published in the journal Gut, the work was led by Dr. Lukas Mager from University Hospital Tübingen alongside Prof. Kathy McCoy of the University of Calgary. The findings suggest a potential shift toward personalized medicine for inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, where patient microbiomes vary significantly and determining whether specific microbes cause disease or merely react to it remains challenging.

To pinpoint disease-promoting organisms, the researchers analyzed stool samples from patients before and after medical interventions like antibiotics or fecal microbiota transplantation. By transferring these microorganisms into germ-free mice and utilizing host immune antibodies to isolate harmful strains, the team identified two specific bacterial species—Sarcina perfringens and Hathewaya massiliensis—that stimulate innate immune cells and provoke inflammation. Further analysis revealed elevated levels of Sarcina perfringens in about 25% to 30% of IBD patients, while Hathewaya massiliensis was elevated in roughly 5%. Laboratory tests using human intestinal organoids confirmed that both species can impair intestinal epithelial cell function.

What to know: The study also screened over 1,500 approved compounds and discovered five substances that selectively inhibit the growth of these two harmful species without disrupting the broader microbiome. Notably, the antibiotic oxolinic acid reduced inflammation in mouse models comparably to broad-spectrum treatments while preserving beneficial microbes. Because these findings are currently based on animal models and laboratory tissue tests, further clinical research is required to determine safety and efficacy in humans. Readers should consult a physician for any personal medical decisions regarding IBD care.

Source Medical Xpress — medicalxpress.com/news/2026-11-personalized-therapies-crohn-ulcerative-… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.